|1.||Gleave, Martin E: 8 articles (09/2011 - 08/2005)|
|2.||Gleave, Martin: 5 articles (09/2014 - 11/2005)|
|3.||Chi, Kim N: 5 articles (01/2013 - 09/2005)|
|4.||Zoubeidi, Amina: 4 articles (09/2014 - 08/2008)|
|5.||Fazli, Ladan: 4 articles (09/2011 - 09/2005)|
|6.||Powers, Jean: 4 articles (09/2010 - 09/2005)|
|7.||Tu, Dongsheng: 3 articles (09/2010 - 09/2005)|
|8.||Lamoureux, Francois: 2 articles (09/2014 - 09/2011)|
|9.||Beraldi, Eliana: 2 articles (08/2013 - 09/2011)|
|10.||Kuruma, Hidetoshi: 2 articles (08/2013 - 09/2011)|
|1.||Lung Neoplasms (Lung Cancer)
05/01/2006 - "There have been four kinds of Phase II studies that have begun to further evaluate the efficacy of OGX-011 in patients with prostate, breast and lung cancers."
11/15/2005 - "Apoptosis was significantly increased when H460 lung cancer cells were treated with OGX-011 plus radiation. "
02/01/2008 - "Phase II trials of combined OGX-011 and chemotherapy are ongoing in patients with prostate, breast, and lung cancers."
11/15/2005 - "A combination of radiotherapy and OGX-011 improved control of tumor growth and vascular regression in the H460 lung cancer model."
|2.||Neoplasm Metastasis (Metastasis)
09/20/2010 - "Baseline factors associated with improved OS on exploratory multivariate analysis were an Eastern Cooperative Oncology Group performance status of 0 (hazard ratio [HR], 0.27; 95% CI, 0.14 to 0.51), presence of bone or lymph node metastases only (HR, 0.45; 95% CI, 0.25 to 0.79), and treatment assignment to OGX-011 (HR, 0.50; 95% CI, 0.29 to 0.87). "
02/20/2015 - "CLU suppression using OGX-011 may represent a promising therapeutic option for suppressing HCC metastasis. "
02/20/2015 - "We further observed that CLU knockdown using the CLU inhibitor OGX-011 significantly suppressed HCC metastasis in two metastatic models through inhibiting EIF3I/Akt/MMP13 signaling. "
02/01/2009 - "Furthermore, OGX-011 chemo-sensitized UM-UC-3R cells to gemcitabine in vitro with a reduction in the concentration that reduces the effect by 50% (IC50) from 100 nm to 10 nm. Tumour volume and the incidence of metastasis in nude mice injected with UM-UC-3R cells was significantly greater than those of nude mice injected with UM-UC-3P cells; however, systemic administration of OGX-011 plus a low dose of gemcitabine significantly suppressed tumour volume and the incidence of metastasis in both groups. "
11/15/2005 - "Doppler studies showed that tumor blood flow was compromised when mice bearing H460 xenografts were treated with OGX-011 and radiation. "
09/01/2011 - "In vivo evaluation of the Hsp90 inhibitors with OGX-011 in xenograft models of human CRPC showed that OGX-011 markedly potentiated antitumor efficacy, leading to an 80% inhibition of tumor growth with prolonged survival compared with Hsp90 inhibitor monotherapy. "
07/01/2009 - "Our data indicate that HDACI-induced clusterin over-expression renders cancer cells resistant to HDACI-induced growth arrest and apoptosis, and suggests the addition of OGX-011 to HDACIs in future clinical trials in cancer patients."
09/07/2005 - "The primary objective of this clinical study was to determine a biologically effective dose of OGX-011 that would inhibit clusterin expression in human cancer. "
01/01/2012 - "Finally, OGX-011 in combination with gemcitabine substantially decreased the in vivo tumor growth and promoted apoptosis. "
|4.||Breast Neoplasms (Breast Cancer)
12/01/2006 - "Phase II clinical trials of OGX-011 in combination with chemotherapeutic drugs are underway in NSCLC, prostate and breast cancer."
01/15/2009 - "The primary objective of this phase II trial was to assess the safety and efficacy of the combination of OGX-011 and docetaxel for metastatic breast cancer. "
01/15/2009 - "Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer."
01/15/2009 - "The combination of OGX-011 and docetaxel at 75 mg/m(2) is well tolerated and clinical activity was seen in these patients with metastatic breast cancer, but there was an insufficient number of responses to meet the criteria for proceeding to the second stage of accrual."
12/01/2005 - "These data identify clusterin as a valid therapeutic target and provides preclinical proof-of-principle to test OGX-011 in multimodality therapies for breast cancer."
|5.||Prostatic Neoplasms (Prostate Cancer)
10/01/2012 - "Two Phase III registration trials are currently under recruitment evaluating OGX-011 in combination with chemotherapy in patients with metastatic castration-resistant prostate cancer. "
09/07/2005 - "A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer."
09/01/2011 - "Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer."
05/01/2006 - "Based on these outcomes, Phase I clinical trials were conducted using AS clusterin ODN incorporating 2'-O-(2-methoxy)ethyl-gapmer backbone (OGX-011), and the optimal dose of OGX-011 capable of inducing </= 90% suppression of clusterin in human prostate cancer tissue was determined. "
09/07/2005 - "Subjects (n = 25) with localized prostate cancer with high-risk features who were candidates for prostatectomy were treated with OGX-011 by 2-hour intravenous infusion on days 1, 3, and 5 and then weekly from days 8-29 combined with androgen blockade starting on day 1; prostatectomy was performed on days 30-36. "
|6.||sorafenib (BAY 43-9006)
|8.||Small Interfering RNA (siRNA)
|9.||Prostate-Specific Antigen (Semenogelase)
|2.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)